SCHEMBL5022945

SCHEMBL5022945

CCOC(=O)[C@H]1CN(C(=O)OCC)C[C@@H]1C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NR1H2 P55055 1/20 0.42
MAPT P10636 3/20 0.40
GAA P10253 1/20 0.38
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE4B Q07343 3/20 0.36
PDE4A P27815 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
THRB P10828 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930654 0.92 NR1H2 (0.50) ALDH1A1TSHRMEN1KMT2ANR1H2
SCHEMBL1052491 0.92 NR1H2 (0.50) ALDH1A1TSHRMEN1KMT2ANR1H2
SCHEMBL2930651 0.92 NR1H2 (0.50) ALDH1A1TSHRMEN1KMT2ANR1H2
SCHEMBL3369192 0.86 NR1H2 (0.46) ALDH1A1TSHRMEN1KMT2ANR1H2
SCHEMBL1053828 0.86 NR1H2 (0.46) ALDH1A1TSHRMEN1KMT2ANR1H2
SCHEMBL3369193 0.86 NR1H2 (0.46) ALDH1A1TSHRMEN1KMT2ANR1H2
Water SCHEMBL1055969 0.85 NR1H2 (0.44) ALDH1A1TSHRMEN1KMT2ANR1H2
Water SCHEMBL1055202 0.85 NR1H2 (0.44) ALDH1A1TSHRMEN1KMT2ANR1H2
SCHEMBL24555863 0.84 NR1H2 (0.47) ALDH1A1TSHRMEN1KMT2ANR1H2
SCHEMBL21564451 0.84 NR1H2 (0.47) ALDH1A1TSHRMEN1KMT2ANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732918-B1 NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-11-12 EP disclosed
EP-1732918-A1 NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-20 EP disclosed
WO-2005092881-A1 NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-10-06 WO disclosed
US-20050215599-A1 Pyrrolidine-3,4-dicarboxamide derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215599-A1 Pyrrolidine-3,4-dicarboxamide derivatives F9, F2, F12 ALDH1A1 1396/4885TSHR 1530/4885MEN1 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.